The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Fungizone     (1R,3S,5R,6R,9R,11R,15S,16R,17 R,18S,19E...

Synonyms: Abelecet, Ambisome, Amphocin, Amphotec, Fungilin, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Tegopen


High impact information on Tegopen


Chemical compound and disease context of Tegopen


Biological context of Tegopen


Anatomical context of Tegopen


Associations of Tegopen with other chemical compounds


Gene context of Tegopen

  • Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4 [30].
  • Fungizone (FZ) and Amphotec (ABCD) caused the release of significantly more inflammatory molecules and the release of inflammatory molecules at higher levels than either AmBisome (L-AMB) or Abelcet (ABLC) after 6 h of treatment [31].
  • The role of IFN-gamma is selective, since it is not a cofactor in the response to AmB [32].
  • Treatment with either Sb or AmB permits an iNOS-independent mechanism to emerge and control residual intracellular L. donovani infection [32].
  • Treatment with AmB, SP-D, and rSP-D increased the survival rate to 80, 60, and 80%, respectively, suggesting that SP-D (and rSP-D) can protect immunosuppressed mice from an otherwise fatal challenge with Aspergillus fumigatus conidia [33].

Analytical, diagnostic and therapeutic context of Tegopen


  1. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Walsh, T.J., Finberg, R.W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R.N., Dummer, S., Schuster, M., Holcenberg, J.S. N. Engl. J. Med. (1999) [Pubmed]
  2. Liposomal amphotericin B for fever and neutropenia. Wingard, J.R. N. Engl. J. Med. (1999) [Pubmed]
  3. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Davidson, R.N., Croft, S.L., Scott, A., Maini, M., Moody, A.H., Bryceson, A.D. Lancet (1991) [Pubmed]
  4. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Ozsahin, H., von Planta, M., Müller, I., Steinert, H.C., Nadal, D., Lauener, R., Tuchschmid, P., Willi, U.V., Ozsahin, M., Crompton, N.E., Seger, R.A. Blood (1998) [Pubmed]
  5. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. Caillot, D., Casasnovas, O., Bernard, A., Couaillier, J.F., Durand, C., Cuisenier, B., Solary, E., Piard, F., Petrella, T., Bonnin, A., Couillault, G., Dumas, M., Guy, H. J. Clin. Oncol. (1997) [Pubmed]
  6. Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. Lopez-Berestein, G., Bodey, G.P., Frankel, L.S., Mehta, K. J. Clin. Oncol. (1987) [Pubmed]
  7. Liposomal amphotericin B therapy in disseminated histoplasmosis. Harten, P., Baron, Y., Euler, H.H. Arch. Intern. Med. (1995) [Pubmed]
  8. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. Coker, R.J., Viviani, M., Gazzard, B.G., Du Pont, B., Pohle, H.D., Murphy, S.M., Atouguia, J., Champalimaud, J.L., Harris, J.R. AIDS (1993) [Pubmed]
  9. Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds. Lazanas, M.C., Tsekes, G.A., Papandreou, S., Harhalakis, N., Scandali, A., Nikiforakis, E., Saroglou, G. AIDS (1993) [Pubmed]
  10. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Wheat, L.J., Cloud, G., Johnson, P.C., Connolly, P., Goldman, M., Le Monte, A., Fuller, D.E., Davis, T.E., Hafner, R. Antimicrob. Agents Chemother. (2001) [Pubmed]
  11. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Clemons, K.V., Espiritu, M., Parmar, R., Stevens, D.A. Antimicrob. Agents Chemother. (2005) [Pubmed]
  12. Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Clemons, K.V., Sobel, R.A., Williams, P.L., Pappagianis, D., Stevens, D.A. Antimicrob. Agents Chemother. (2002) [Pubmed]
  13. Posaconazole prophylaxis in experimental systemic zygomycosis. Barchiesi, F., Spreghini, E., Santinelli, A., Fothergill, A.W., Pisa, E., Giannini, D., Rinaldi, M.G., Scalise, G. Antimicrob. Agents Chemother. (2007) [Pubmed]
  14. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. Francis, P., Lee, J.W., Hoffman, A., Peter, J., Francesconi, A., Bacher, J., Shelhamer, J., Pizzo, P.A., Walsh, T.J. J. Infect. Dis. (1994) [Pubmed]
  15. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Hong, Y., Shaw, P.J., Nath, C.E., Yadav, S.P., Stephen, K.R., Earl, J.W., McLachlan, A.J. Antimicrob. Agents Chemother. (2006) [Pubmed]
  16. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Coukell, A.J., Brogden, R.N. Drugs (1998) [Pubmed]
  17. Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis. Falk, R., Grunwald, J., Hoffman, A., Domb, A.J., Polacheck, I. Antimicrob. Agents Chemother. (2004) [Pubmed]
  18. Enhancement of the treatment of experimental candidiasis with vascular decongestants. Luke, D.R., Wasan, K.M., McQueen, T.J., Lopez-Berestein, G. J. Infect. Dis. (1990) [Pubmed]
  19. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Walsh, T.J., Goodman, J.L., Pappas, P., Bekersky, I., Buell, D.N., Roden, M., Barrett, J., Anaissie, E.J. Antimicrob. Agents Chemother. (2001) [Pubmed]
  20. Does transmembrane communication through gap junctions enable stem cells to overcome stromal inhibition? Rosendaal, M., Mayen, A., de Koning, A., Dunina-Barkovskaya, T., Krenács, T., Ploemacher, R. Leukemia (1997) [Pubmed]
  21. Effects of free and liposomal amphotericin B and gramicidin S alone and in combination on potassium leakage from human erythrocytes and Candida albicans. Midez, J.A., Hopfer, R.L., Lopez-Berestein, G., Mehta, R.T. Antimicrob. Agents Chemother. (1989) [Pubmed]
  22. Role of macrophages in the candidacidal activity of liposomal amphotericin B. Mehta, R.T., Poddar, S., Kalidas, M., Gomez-Flores, R., Dulski, K. J. Infect. Dis. (1997) [Pubmed]
  23. Influence of liposomal amphotericin B on CD8 T-cell function. Kretschmar, M., Geginat, G., Bertsch, T., Walter, S., Hof, H., Nichterlein, T. Antimicrob. Agents Chemother. (2001) [Pubmed]
  24. Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus. Roilides, E., Lyman, C.A., Filioti, J., Akpogheneta, O., Sein, T., Lamaignere, C.G., Petraitiene, R., Walsh, T.J. Antimicrob. Agents Chemother. (2002) [Pubmed]
  25. Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformans. Hossain, M.A., Maesaki, S., Kakeya, H., Noda, T., Yanagihara, K., Sasaki, E., Hirakata, Y., Tomono, K., Tashiro, T., Kohno, S. Antimicrob. Agents Chemother. (1998) [Pubmed]
  26. Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Schinabeck, M.K., Long, L.A., Hossain, M.A., Chandra, J., Mukherjee, P.K., Mohamed, S., Ghannoum, M.A. Antimicrob. Agents Chemother. (2004) [Pubmed]
  27. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Ibrahim, A.S., Avanessian, V., Spellberg, B., Edwards, J.E. Antimicrob. Agents Chemother. (2003) [Pubmed]
  28. Effects of antifungal agents on the function of human neutrophils in vitro. Roilides, E., Walsh, T.J., Rubin, M., Venzon, D., Pizzo, P.A. Antimicrob. Agents Chemother. (1990) [Pubmed]
  29. In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus. Otsubo, T., Maesaki, S., Hossain, M.A., Yamamoto, Y., Tomono, K., Tashiro, T., Seki, J., Tomii, Y., Sonoke, S., Kohno, S. Antimicrob. Agents Chemother. (1999) [Pubmed]
  30. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. Bellocchio, S., Gaziano, R., Bozza, S., Rossi, G., Montagnoli, C., Perruccio, K., Calvitti, M., Pitzurra, L., Romani, L. J. Antimicrob. Chemother. (2005) [Pubmed]
  31. Antibody array-generated profiles of cytokine release from THP-1 leukemic monocytes exposed to different amphotericin B formulations. Turtinen, L.W., Prall, D.N., Bremer, L.A., Nauss, R.E., Hartsel, S.C. Antimicrob. Agents Chemother. (2004) [Pubmed]
  32. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Murray, H.W., Delph-Etienne, S. Infect. Immun. (2000) [Pubmed]
  33. Protective role of lung surfactant protein D in a murine model of invasive pulmonary aspergillosis. Madan, T., Kishore, U., Singh, M., Strong, P., Hussain, E.M., Reid, K.B., Sarma, P.U. Infect. Immun. (2001) [Pubmed]
  34. Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B. Shirkhoda, A., Lopez-Berestein, G., Holbert, J.M., Luna, M.A. Radiology. (1986) [Pubmed]
  35. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Olson, J.A., Adler-Moore, J.P., Smith, P.J., Proffitt, R.T. Antimicrob. Agents Chemother. (2005) [Pubmed]
  36. Prophylactic administration of liposomal amphotericin B is superior to treatment in a murine model of invasive aspergillosis after hematopoietic cell transplantation. BitMansour, A., Brown, J.M. J. Infect. Dis. (2002) [Pubmed]
  37. Successful treatment of mucor infection after liver or pancreas-kidney transplantation. Jiménez, C., Lumbreras, C., Aguado, J.M., Loinaz, C., Paseiro, G., Andrés, A., Morales, J.M., Sánchez, G., García, I., del Palacio, A., Moreno, E. Transplantation (2002) [Pubmed]
  38. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Adedoyin, A., Bernardo, J.F., Swenson, C.E., Bolsack, L.E., Horwith, G., DeWit, S., Kelly, E., Klasterksy, J., Sculier, J.P., DeValeriola, D., Anaissie, E., Lopez-Berestein, G., Llanos-Cuentas, A., Boyle, A., Branch, R.A. Antimicrob. Agents Chemother. (1997) [Pubmed]
WikiGenes - Universities